GLYCERYL 2-PHOSPHATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C3H9O6P
Molecular Weight	172.0737
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OCC(CO)OP(O)(O)=O

InChI

InChIKey=DHCLVCXQIBBOPH-UHFFFAOYSA-N

InChI=1S/C3H9O6P/c4-1-3(2-5)9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)

HIDE SMILES / InChI

Molecular Formula	C3H9O6P
Molecular Weight	172.0737
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/ppa/sodium-glycerophosphate-pentahydrate.html | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | http://www.medsafe.govt.nz/profs/Datasheet/g/Glycophosinf.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/573222 | https://www.ncbi.nlm.nih.gov/pubmed/22961670 | https://www.ncbi.nlm.nih.gov/pubmed/15265286https://www.ncbi.nlm.nih.gov/pubmed/19275097 | https://www.ncbi.nlm.nih.gov/pubmed/929612 | https://www.ncbi.nlm.nih.gov/pubmed/4140270 | https://www.scbt.com/scbt/it/product/beta-glycerophosphate-disodium-salt-pentahydrate-13408-09-8 | https://www.ncbi.nlm.nih.gov/pubmed/22383088

Sodium glycerol 2-phosphate (Disodium beta-glycerophosphate) is used for the preparation of thermo-sensitive chitosan hydrogen as a scaffold to construct tissue engineered injectable nucleus pulposus (NP). Since Sodium glycerol 2-phosphate (6 g/day) reduced the lithogenic index of bile in human subjects with cholesterol gallstones in a short-term study and facilitated dissolution of cholesterol gallstones in mice, Sodium glycerol 2-phosphate may have potential to help dissolve cholesterol gallstones in man. Sodium glycerol 2-phosphate is an alkaline phosphate inhibitor. Sodium β-glycerophosphate pentahydrate is used as a phosphatase inhibitor. It promotes bone matrix mineralization while delivering to osteoblasts by providing a source of phosphate ions. It is used in the development of hydrogels and scaffolds, which finds applications in tissue engineering and cell growth. It is used as an additive in isolation mediums by providing phosphate ions to isolate. It is utilized to promote mineralization in vitro by modulating bone cell metabolic activity.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Alkaline phosphatase, tissue-nonspecific isozyme 19 Target ID: CHEMBL5979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22383088	Inhibitor 8297
Protein phosphatase 3 Target ID: Protein phosphatase Sources: https://www.alfa.com/en/catalog/L03425/ \| https://www.ncbi.nlm.nih.gov/pubmed/9348078 \| http://www.merckmillipore.com/RU/ru/product/%CE%B2-Glycerophosphate%2C-Disodium-Salt%2C-Pentahydrate---CAS-13408-09-8---Calbiochem,EMD_BIO-35675?ReferrerURL=https%3A%2F%2Fwww.google.ru%2F	Inhibitor 8297
Glycerol-2-phosphatase 3 Target ID: Glycerol-2-phosphatase Sources: http://www.rsc.org/publishing/journals/prospect/ontology.asp?id=GO:0047954&MSID=B915913B	Substrate 661

Conditions

Condition	Modality	Highest Phase	Product
Uterine diseases 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13167694	Primary	Not Provided 504	Unknown Approved Use Unknown
Intervertebral disc degradation 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19275097 https://www.ncbi.nlm.nih.gov/pubmed/20695376	Primary	Basic research	Unknown Approved Use Unknown
Cholelithiasis 14 Sources: https://www.ncbi.nlm.nih.gov/pubmed/929612 https://www.ncbi.nlm.nih.gov/pubmed/4140270	Primary	Preclinical	Unknown Approved Use Unknown
Caries 43 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1060200	Primary	Basic research	Unknown Approved Use Unknown
Nutritional requirements 5 Sources: https://www.drugs.com/pro/glycophos-injection.html https://www.fda.gov/downloads/drugs/drugsafety/drugshortages/ucm354277.pdf	Primary	Approved 8429	Glycophos Approved Use Glycophos is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.
Cholelithiasis 14 Sources: https://www.ncbi.nlm.nih.gov/pubmed/573222	Primary	Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effect of oral administration of 'essential' phospholipid, beta-glycerophosphate, and linoleic acid on biliary lipids in patients with cholelithiasis.	1979	573222
Pericytes derived from the retinal microvasculature undergo calcification in vitro.	1990 Nov	2074265
Mechanism of action of beta-glycerophosphate on bone cell mineralization.	1992 Oct	1422975
Biomimetic apatite coatings on micro-arc oxidized titania.	2004 Aug	15020106
Bone regeneration by grafting of cultured human bone.	2004 May-Jun	15265286
Enhancing effect of daidzein on the differentiation and mineralization in mouse osteoblast-like MC3T3-E1 cells.	2006 Aug	16880723
Antibacterial properties of Ag (or Pt)-containing calcium phosphate coatings formed by micro-arc oxidation.	2009 Jan	18286618
[Comparison study on injectable tissue engineered nucleus pulposus constructed by different cells and chitosan hydrogel].	2010 Jul	20695376
Taurine suppresses osteoblastic differentiation of aortic valve interstitial cells induced by beta-glycerophosphate disodium, dexamethasone and ascorbic acid via the ERK pathway.	2012 Oct	22383088
Generation of osteogenic construct using periosteal-derived osteoblasts and polydioxanone/pluronic F127 scaffold with periosteal-derived CD146 positive endothelial-like cells.	2013 Apr	22961670
The extracellular matrix protein Edil3 stimulates osteoblast differentiation through the integrin α5β1/ERK/Runx2 pathway.	2017	29182679
Bone regeneration with osteogenic matrix cell sheet and tricalcium phosphate: An experimental study in sheep.	2017 Oct 18	29094005
Alendronate-loaded, biodegradable smart hydrogel: a promising injectable depot formulation for osteoporosis.	2018 Aug	29073792
In vitro and in vivo acute response towards injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofiber hydrogel.	2018 Jan 15	29103503

Patents

Sample Use Guides

In Vivo Use Guide

Dose Adults: The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 mL of GLYCOPHOS (Sodium glycerophosphate pentahydrate) added to the infusion solution or to the admixture for which compatibility has been proved. Children, Infants and Neonates: The recommended dosage is individual. The recommended dose for children, infants and neonates is 1.0-1.5 mmol/kg body weight/day. Method of administration Intravenous Infusion. GLYCOPHOS must not be given undiluted. The infusion time should not be less than 8 hours.

Route of Administration: Intravenous

In Vitro Use Guide

Medium supplementation with beta-GP (Sodium 2-glycerophosphate) should not exceed 2 mM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:38:16 UTC 2023` Edited by `admin` on `Fri Dec 15 15:38:16 UTC 2023`
Record UNII	WWH06G87W6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GLYCERYL 2-PHOSPHATE

Common Name

English

GLYCEROL, 2-(DIHYDROGEN PHOSPHATE)

Common Name

English

GLYCEROPHOSPHORIC ACID .BETA.-FORM

Common Name

English

.BETA.-GLYCEROPHOSPHATE

Common Name

English

2-GLYCEROPHOSPHORIC ACID

Common Name

English

.BETA.-GLYCERYL PHOSPHATE

Common Name

English

GLYCEROL 2-PHOSPHATE

Common Name

English

1,2,3-PROPANETRIOL, 2-(DIHYDROGEN PHOSPHATE)

Common Name

English

DIHYDROGEN .BETA.-GLYCEROPHOSPHATE

Common Name

English

GLYCEROPHOSPHORIC ACID .BETA.-FORM [MI]

Common Name

English

.BETA.-GLYCEROPHOSPHORIC ACID

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID1023106